SAN DIEGO, Nov. 11 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals
Corporation (TSX: NVN) today announced financial results for the third
quarter and nine months ended September 30, 2008, and highlighted several
recent product developments and corporate milestones.
Recent product and corporate highlights:
o On October 8, 2008, the company announced that it will initiate a
corporate restructuring that will extend the company's financial
resources to pursue near-term corporate development opportunities,
including completion of a merger and acquisition (M&A) transaction,
the sale of specific programs, and/or completion of other
alternative financial arrangements.
o The company announced positive clinical results from its Phase 1
trial of HspE7, a therapeutic treatment for patients with cervical
intraepithelial neoplasia, or CIN, a precursor to cervical cancer.
During the third quarter, immunological data from the fourth and
final cohort of the Phase 1 trial demonstrated absolute levels of
HPV16 E7-specific T-cells in patients were similar to levels
observed in the third cohort. Patients in the fourth cohort were
administered 500 mcg of HspE7 and 2,000 mcg of Poly-ICLC. These data
support doses of 500 mcg of HspE7 and 1,000-2,000 mcg of Poly ICLC
as appropriate for advancing into Phase 2 studies.
o During the quarter, the company won a challenge to its European
patent covering the company's lead product candidate, HspE7, and
other human papillomavirus (HPV) therapeutics.
o Nventa presented positive data from preclinical studies using its
proprietary Toll-like Receptor 3 agonis
|SOURCE Nventa Biopharmaceuticals Corporation|
Copyright©2008 PR Newswire.
All rights reserved